The FDA plans public meeting to encourage generic competition; Mylan reportedly offered rebates to six Medicaid programs; Republicans to present draft bill for Obamacare replacement
The FDA recently proposed studies designed to determine how disclosures in drug ads affect how viewers frame information.
Insurance companies balk at expensive PCSK9 inhibitors; Publicis to focus investments on AI platform; clinical trial reveals Novartis' eye drug requires less frequent injections
Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
Apple reportedly working to bring EMRs to iPhone; FDA to study disclosures in ads; Trump admin discussing drug price EO
The FDA-approved app will allow MS patients to share their medication injection history with HCPs.
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus' Neulasta biosimilar; only 17% of Americans find health industries to be innovative
The bill, introduced in March, is being considered as an amendment in the upcoming PDUFA reauthorization legislation.
50% of consumers say they will share their health data with tech giants; pharma CEOs expect pricing proposal from Trump administration; FDA approves generic versions of Strattera
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
The regulator also took issue with how Orexigen Therapeutics presented the risk information
Disease awareness ads can boost drug sales; AstraZeneca's experimental asthma drug cuts steroid use; FDA approves Regeneron and Sanofi's RA drug
Amgen's osteoporosis drug set back by safety issue; new FDA digital biz to hire 13 engineers; Celgene's MS drug bests Avonex in trial
FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations
The former FDA commissioner said marketers need to focus on ensuring that off-label promotion is "non-misleading."
FDA approves Merck/Lilly combo for lung cancer; new PhRMA requirements result in expulsion of 22 members; Pfizer to pay Sangamo $7 million for gene therapy programs
The Senate confirms Gottlieb as FDA commissioner; Endo shares DTC plans for Xiaflex; an AstraZeneca asthma drug fails in late-stage study
The FDA approves osteoporosis drug; groups warn that latest healthcare bill would cut protections for pre-existing conditions; Dupixent gets PBM coverage
Express Scripts-Anthem deal highlights profitability for PBMs; Sarepta CEO steps down; study says NHS cancer drug fund was ineffective
GSK warns Advair generic competition may affect business in 2017; Lilly plans to meet FDA about baricitinib; FDA warns companies selling 'illegal' products
Novartis gets Breakthrough designation for its CAR-T therapy; Duchesney continues working with Kardashian; new user-fee deal to speed up FDA approvals
The FDA rejected an outcomes update to the Januvia label; digital-health funding dropped in Q1 of 2017; the FDA approves 23andMe's genetic test
The FDA approves drugs faster than EMA; Botox goes to late-stage testing for depression; GSK recalls nearly 600,000 asthma inhalers
Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.
PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.
The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits